D
David Gilligan
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 64
Citations - 2365
David Gilligan is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 55 publications receiving 1843 citations. Previous affiliations of David Gilligan include University of Cambridge & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
TL;DR: A review of the literature and evidence on therapy options after EGFR tyrosine kinase inhibitors (TKIs) treatment for non-small-cell lung cancer (NSCLC) is presented in this paper.
Journal ArticleDOI
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
David Gilligan,Marianne Nicolson,Ian E. Smith,Harry J.M. Groen,Otilia Dalesio,Peter Goldstraw,Matthew Hatton,Penelope Hopwood,Christian Manegold,Franz M.N.H. Schramel,Hans Smit,Jan P. van Meerbeeck,Matthew Nankivell,Mahesh K. B. Parmar,C. Pugh,Richard Stephens +15 more
TL;DR: There was no evidence of a difference in overall survival with neo-adjuvant chemotherapy, but the result is statistically consistent with previous trials, and therefore adds considerable weight to the current evidence.
Journal ArticleDOI
Performance status score: do patients and their oncologists agree?
TL;DR: There was no sex difference in patient assessment of PS scores, but oncologists scored female patients more pessimistically than males, and it may benefit their clinical practice to involve their patients in these assessments.
Journal ArticleDOI
Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis
Stephen G. Spiro,LE James,Robin M. Rudd,C. Trask,Jeffrey S Tobias,Michael Snee,David Gilligan,Philip A. Murray,Mary Carmen Ruiz de Elvira,Katy M. O'Donnell,N.H. Gower,Peter Harper,Allan Hackshaw +12 more
TL;DR: This study failed to show a survival advantage for early TRT with chemotherapy in limited-stage SCLC, unlike the NCIC trial, but the results of a meta-analysis suggest that it is essential to ensure that the delivery of chemotherapy is optimal when administered with earlyTRT.
Journal ArticleDOI
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Peter W. Szlosarek,Peter W. Szlosarek,Jeremy P.C. Steele,Luke Nolan,David Gilligan,Paul Taylor,James Spicer,Michael J. Lind,Sankhasuvra Mitra,Jonathan Shamash,Melissa Phillips,Melissa Phillips,Phuong Luong,Sarah Payne,Paul Hillman,Stephen Ellis,Teresa Szyszko,Gairin Dancey,Lee M. Butcher,Stephan Beck,Norbert Avril,Jim Thomson,Amanda Johnston,Marianne Tomsa,Cheryl Lawrence,Peter Schmid,Peter Schmid,Tim Crook,Bor Wen Wu,John S. Bomalaski,Nicholas R. Lemoine,Michael Sheaff,Robin M. Rudd,D.A. Fennell,Allan Hackshaw +34 more
TL;DR: In this trial, arginine deprivation with ADI-PEG20 improved PFS in patients with ASS1-deficient malignant pleural mesothelioma and warrants further clinical investigation inArginine-dependent cancers.